In the randomized phase 3 NEMO trial, comparing the MEK-inhibitor binimetinib to dacarbazine chemotherapy in patients with advanced NRASQ61R/K/L mutant melanoma, binimetinib treatment resulted in a significantly improved objective response rate (ORR, 15% versus 7%) and median progression-free survival (PFS, 2.8 versus 1.5 months, p < 0.001), but not OS (11.0 versus 10.1 months, p < 0.50) [5]. This evidence concerns the gene MAP2K7 and melanoma.